News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

Year: 2013

Epigenomics signs licensing agreement with BioChain for Septin9 in China

07.03.2013 | 130307_Epigenomics_Press_release_BioChain Berlin, Germany, Seattle, WA, and San Francisco, CA, U.S.A., Beijing, China – Epigenomics AG (Frankfurt Prime Standard: ECX), the German-American cancer molecular diagnostics company, and BioChain, a leading Clinical Diagnostics company in cancer and genetic tests, today announced that BioChain has licensed Epigenomics’ methylated Septin9 marker for the blood based detection of […]

Read more

Epigenomics receives notification of priority review status and acceptance for filing by FDA of PMA application for Epi proColon®

21.02.2013 | 130221_Press_release_Epigenomics_AG_PMA_filing Berlin, Germany, and Seattle, WA, U.S.A.  – Epigenomics AG (Frankfurt Prime Standard: ECX), the German-American cancer molecular diagnostics company, announced today that the United States Food & Drug Administration (FDA) accepted its Premarket Approval (PMA) application for Epi proColon®. The agency concluded that all information needed for the substantive review is included […]

Read more

Predictive Biosciences launches prostate cancer test based on Epigenomics’ DNA methylation marker

29.01.2013 | 130129_Press_release_Epigenomics_AG_Predictive Berlin, Germany, Seattle, WA, and Lexington, MA, U.S.A. – Epigenomics AG (Frankfurt Prime Standard: ECX), the German-American cancer molecular diagnostics company, and Predictive Biosciences, an innovative developer of molecular diagnostic tests, today announced that Predictive Biosciences of Lexington, MA, has made commercially available a novel tissue-based test for prostate cancer biopsy confirmation […]

Read more

Epigenomics AG submits the fourth module and completes its PMA submission to the FDA for Epi proColon®

07.01.2013 | 130107_Press_release_Epigenomics_AG_fourth_module Berlin, Germany, and Seattle, WA, U.S.A. – Epigenomics AG (Frankfurt Prime Standard: ECX), the German-American cancer molecular diagnostics company, announced today that it has submitted the fourth and final module of its Premarket Approval (PMA) to the United States Food & Drug Administration (FDA) for its blood-based Epi proColon® test for the […]

Read more